Antimalarial Drug Resistance and Prevention of Malaria During Pregnancy; Notice of Intent To Fund Single Eligibility Award, 16505 [05-6344]

Download as PDF Federal Register / Vol. 70, No. 61 / Thursday, March 31, 2005 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Antimalarial Drug Resistance and Prevention of Malaria During Pregnancy; Notice of Intent To Fund Single Eligibility Award A. Purpose The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2005 funds for a cooperative agreement program to increase the epidemiological and operational data generated in the West African sub-region upon which policy makers can base their decisions and bring cutting edge malaria control tools from the bench to the field. The Catalog of Federal Domestic Assistance number for this program is 93.283. B. Eligible Applicant Assistance will be provided only to the Malarial Research and Training Center (MRTC), Department of Epidemiology and Parasitic Diseases, Faculty of Medicine and Dentistry, University of Bamako, Mali. The Malaria Research and Training Center (MRTC) is the only institution in West Africa that has the experience and infrastructure required. The MRTC designed and developed the Genotype Resistance Index (GRI), a crucial component of the proposed work. MRTC has also conducted the only full scale randomized controlled trial comparing chemoprophylaxis and intermittent preventive treatment for the prevention of malaria during pregnancy. They have demonstrated through this and other field-based and laboratorybased research projects that they are capable of executing complex scientific malaria research. MRTC is housed under the Department of Epidemiology and Parasitic Diseases, Faculty of Medicine, Pharmacy, and Dentistry, University of Bamako, Mali. The MRTC was founded in 1992 to conduct laboratory and field research related to malaria. Units within MRTC include Entomology and Molecular Biology, Vector Ecology, Malaria during Pregnancy, Transmission Blocking Vaccine Unit, GIS Unit, Parasite Epidemiology, Malaria Vaccine Development Unit, Biostatistics and Data Management, Drug Resistance/ Molecular Biology, Parasite Immunology and Immunogenetics, Parasite Molecular Biology, and Informatics. Because of its institutional linkages with the Ministry of Health, including the National Malaria Control VerDate jul<14>2003 15:30 Mar 30, 2005 Jkt 205001 Program, MRTC is able to share its research findings and work with the Ministry of Health to adapt them into policy and programs. For more than a decade, MRTC has been working with all levels of the Ministry of Health to conduct health research. MRTC conducts its own data entry and has developed and built data management and analytic capacity within the Center. The team at MRTC has extensive experience in the conduct of in vivo antimalarial drug efficacy studies, supporting laboratory investigations (molecular marker identification, measurement of antimalarial drug levels, identification of P. falciparum phenotype, and in vitro efficacy studies), and the conduct of malaria during pregnancy research. MRTC scientists and collaborators have numerous published scientific papers indicating the scientific soundness of research conducted by the Center. The combination of access and an institutional linkage to the Ministry of Health, experience conducting antimalarial drug resistance work in Mali, equipment for the conduct of polymerase chain reaction (PCR), laboratory expertise in P. falciparum antimalarial drug resistance marker identification, international stature in research on malaria during pregnancy, experience in conducting trials regarding malaria during pregnancy in Mali, the expertise to read placental malaria blood slides, an infrastructure capable of data management and analysis, and a reputation for conducting sound scientific work makes MRTC the only organization with these attributes and the only vendor who can perform the necessary work. C. Funding Approximately $100,000 is available in FY 2005 to fund this award. It is expected that the award will begin on or before June 1, 2005 and will be made for a 12-month budget period within a project period of up to five years. Funding estimates may change. D. Where To Obtain Additional Information For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: 770–488–2700. For technical questions about this program, contact: Dr. Trudy Messmer, Scientific Review Administer, 1600 Clifton Road, MS C–19, Atlanta, GA 30333, Telephone: (404) 639–3770, Email: TMessmer@cdc.gov. PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 16505 Dated: March 25, 2005. William P. Nichols, Director, Procurement and Grants Office, Centers for Disease Control and Prevention. [FR Doc. 05–6344 Filed 3–30–05; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Mining Occupational Safety and Health Research, Request for Application OH–05–005 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting: Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Mining Occupational Safety and Health Research, Request for Application OH–05–005. Times and Dates: 6 p.m.–8 p.m., April 19, 2005 (Closed). 8 a.m.–5 p.m., April 20, 2005 (Closed). 8 a.m.–5 p.m., April 21, 2005 (Closed). Place: Embassy Suites Hotel, 1900 Diagonal Road, Alexandria, VA 22314, telephone (703) 684–5900. Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Mining Occupational Safety and Health Research, Request for Application OH–05–005. Contact Person For More Information: George Bockosh, MS, Scientific Review Administrator, National Institute for Occupational Safety and Health, CDC, National Personal Protective Technology Laboratory, 626 Cochrans Mill Road, Pittsburgh, PA 15236, Telephone (412) 386– 6465. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: March 25, 2005. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 05–6345 Filed 3–30–05; 8:45 am] BILLING CODE 4163–19–P E:\FR\FM\31MRN1.SGM 31MRN1

Agencies

[Federal Register Volume 70, Number 61 (Thursday, March 31, 2005)]
[Notices]
[Page 16505]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6344]



[[Page 16505]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Antimalarial Drug Resistance and Prevention of Malaria During 
Pregnancy; Notice of Intent To Fund Single Eligibility Award

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
intent to fund fiscal year (FY) 2005 funds for a cooperative agreement 
program to increase the epidemiological and operational data generated 
in the West African sub-region upon which policy makers can base their 
decisions and bring cutting edge malaria control tools from the bench 
to the field. The Catalog of Federal Domestic Assistance number for 
this program is 93.283.

B. Eligible Applicant

    Assistance will be provided only to the Malarial Research and 
Training Center (MRTC), Department of Epidemiology and Parasitic 
Diseases, Faculty of Medicine and Dentistry, University of Bamako, 
Mali.
    The Malaria Research and Training Center (MRTC) is the only 
institution in West Africa that has the experience and infrastructure 
required. The MRTC designed and developed the Genotype Resistance Index 
(GRI), a crucial component of the proposed work. MRTC has also 
conducted the only full scale randomized controlled trial comparing 
chemoprophylaxis and intermittent preventive treatment for the 
prevention of malaria during pregnancy. They have demonstrated through 
this and other field-based and laboratory-based research projects that 
they are capable of executing complex scientific malaria research. MRTC 
is housed under the Department of Epidemiology and Parasitic Diseases, 
Faculty of Medicine, Pharmacy, and Dentistry, University of Bamako, 
Mali. The MRTC was founded in 1992 to conduct laboratory and field 
research related to malaria. Units within MRTC include Entomology and 
Molecular Biology, Vector Ecology, Malaria during Pregnancy, 
Transmission Blocking Vaccine Unit, GIS Unit, Parasite Epidemiology, 
Malaria Vaccine Development Unit, Biostatistics and Data Management, 
Drug Resistance/Molecular Biology, Parasite Immunology and 
Immunogenetics, Parasite Molecular Biology, and Informatics. Because of 
its institutional linkages with the Ministry of Health, including the 
National Malaria Control Program, MRTC is able to share its research 
findings and work with the Ministry of Health to adapt them into policy 
and programs. For more than a decade, MRTC has been working with all 
levels of the Ministry of Health to conduct health research. MRTC 
conducts its own data entry and has developed and built data management 
and analytic capacity within the Center. The team at MRTC has extensive 
experience in the conduct of in vivo antimalarial drug efficacy 
studies, supporting laboratory investigations (molecular marker 
identification, measurement of antimalarial drug levels, identification 
of P. falciparum phenotype, and in vitro efficacy studies), and the 
conduct of malaria during pregnancy research. MRTC scientists and 
collaborators have numerous published scientific papers indicating the 
scientific soundness of research conducted by the Center.
    The combination of access and an institutional linkage to the 
Ministry of Health, experience conducting antimalarial drug resistance 
work in Mali, equipment for the conduct of polymerase chain reaction 
(PCR), laboratory expertise in P. falciparum antimalarial drug 
resistance marker identification, international stature in research on 
malaria during pregnancy, experience in conducting trials regarding 
malaria during pregnancy in Mali, the expertise to read placental 
malaria blood slides, an infrastructure capable of data management and 
analysis, and a reputation for conducting sound scientific work makes 
MRTC the only organization with these attributes and the only vendor 
who can perform the necessary work.

C. Funding

    Approximately $100,000 is available in FY 2005 to fund this award. 
It is expected that the award will begin on or before June 1, 2005 and 
will be made for a 12-month budget period within a project period of up 
to five years. Funding estimates may change.

D. Where To Obtain Additional Information

    For general comments or questions about this announcement, contact: 
Technical Information Management, CDC Procurement and Grants Office, 
2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2700.
    For technical questions about this program, contact: Dr. Trudy 
Messmer, Scientific Review Administer, 1600 Clifton Road, MS C-19, 
Atlanta, GA 30333, Telephone: (404) 639-3770, E-mail: TMessmer@cdc.gov.

    Dated: March 25, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention.
[FR Doc. 05-6344 Filed 3-30-05; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.